January 22, 2024 11:01 AM EST
People
Pharma

In bid to ex­tend cash run­way, Cara to lay off work­ers, dis­con­tin­ue PhI­II pro­gram in chron­ic kid­ney dis­ease

Anna Brown

News Reporter

Cara Ther­a­peu­tics is cut­ting its work­force by near­ly 50% and end­ing a Phase III pro­gram in­ves­ti­gat­ing an oral ver­sion of its opi­oid pep­tide in pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times